Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 46, Issue 4, pp 551–558 | Cite as

Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

  • Ido Weinberg
  • Jay Giri
  • Raghu Kolluri
  • Juan Ignacio Arcelus
  • Conxita Falgá
  • Silvia Soler
  • Andrei Braester
  • José Bascuñana
  • Javier Gutiérrez-Guisado
  • Manuel Monreal
  • RIETE Investigators
Article

Abstract

Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient outcomes have not been described. Patients from the “Registro Informatizado Enfermedad TromboEmbolica” who had confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, treatment and outcomes including recurrent VTE, bleeds or death were compared. A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P < 0.0001) and had less history of VTE [5.9% vs. 20%, OR 0.26 (0.11–0.59)]. Among patients with isolated DVT, there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06–0.19)]. Treatment duration was shorter in the post-arthroscopy group (174 ± 140 vs. 311 ± 340 days, P < 0.0001) and more often with DOAC [OR 3.67 (1.95–6.89)]. Recurrent VTE occurred in 6.18 (1.96–14.9) and 11.9 (11.0–12.8) per 100 patient years [HR 0.52 (0.16–1.26)] after treatment in the post-arthroscopy and unprovoked groups, respectively. Recurrent VTE occurred in 5.17 (1.31–14.1) per 100 patient years in a separate post bone-fracture group (n = 147), also not statistically different than the post-arthroscopy recurrence rate. After anticoagulation cessation, some patients post-knee arthroscopy develop VTE. While our small sample size precludes drawing firm conclusions, this signal should warrant further research into the optimal treatment duration for these patients, as some patients may be at increased risk for long-term recurrence.

Keywords

Venous thromboembolism Arthroscopy Anticoagulation Knee arthroscopy Deep vein thrombosis Pulmonary embolism 

Notes

Acknowledgements

We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain, which accounts for a 25.02% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma Madrid and Silvia Galindo, both Statistical Advisors in S&H Medical Science Service for the statistical analysis of the data presented in this paper.

Coordinator of the RIETE Registry: Dr. Manuel Monreal (Spain). RIETE Steering Committee Members: Dr. Paolo Prandoni (Italy), Dr. Benjamin Brenner (Israel), Dr. Dominique Farge-Bancel (France). RIETE National Coordinators: Dr. Raquel Barba (Spain), Dr. Pierpaolo Di Micco (Italy), Dr. Laurent Bertoletti (France), Dr. Inna Tzoran (Israel), Dr. Abilio Reis (Portugal), Dr. Henri Bounameaux (Switzerland), Dr. Radovan Malý (Czech Republic), Dr. Peter Verhamme (Belgium), Dr. Marijan Bosevski (Republic of Macedonia), Dr. Joseph A. Caprini (USA), Dr. Hanh My Bui (Vietnam). RIETE Registry Coordinating Center: S & H Medical Science Service. Members of the RIETE Group: Spain: Adarraga MD, Agudo P, Aibar MA, Aibar J, Amado C, Akasbi M, Aranda C, Arcelus JI, Arenas A, Ballaz A, Barba R, Barrón M, Barrón-Andrés B, Bascuñana J, Blanco-Molina A, Camon AM, Carrasco C, Castro J, Cruz AJ, de Ancos C, del Toro J, Demelo P, Díaz-Pedroche MC, Díaz-Peromingo JA, Falgá C, Farfán AI, Fernández-Capitán C, Fidalgo MA, Font C, Font L, García MA, García-Bragado F, García-Morillo M, García-Raso A, Gavín O, Gayol MC, Gil-Díaz A, Gómez V, González-Martínez J, Grau E, Gutiérrez J, Hernández-Blasco L, Iglesias M, Jara-Palomares L, Jaras MJ, Jiménez D, Jou I, Joya MD, Lalueza A, Lima J, Llamas P, Lobo JL, López-Jiménez L, López-Miguel P, López-Nuñez JJ, López-Reyes R, López-Sáez JB, Lorente MA, Lorenzo A, Loring M, Loscos S, Lumbierres M, Marchena PJ, Martín-Fernández M, Martín-Guerra JM, Martín-Romero M, Mellado M, Modesto M, Monreal M, Morales MV, Nieto JA, Núñez A, Núñez MJ, Olivares MC, Otalora S, Otero R, Pedrajas JM, Pellejero G, Pérez-Jacoiste A, Pérez-Rus G, Peris ML, Pesce ML, Porras JA, Rivas A, Rodríguez-Dávila MA, Rodríguez-Fernández L, Rodríguez-Hernández A, Rosa V, Rosillo-Hernández EM, Rubio CM, Ruiz-Alcaraz S, Ruiz-Artacho P, Ruiz-Ruiz J, Ruiz-Sada P, Sahuquillo JC, Sampériz A, Sánchez-Muñoz-Torrero JF, Sancho T, Sanoja ID, Soler S, Soto MJ, Suriñach JM, Tapia E, Torres MI, Trujillo-Santos J, Uresandi F, Usandizaga E, Valle R, Vela JR, Vilar C, Argentina: Gutiérrez P, Vázquez FJ, Vilaseca A, Belgium: Vanassche T, Vandenbriele C, Verhamme P, Brazil: Yoo HHB, Czech Republic: Hirmerova J, Malý R, Ecuador: Salgado E, France: Benzidia I, Bertoletti L, Bura-Riviere A, Debourdeau P, Falvo N, Farge-Bancel D, Hij A, Mahé I, Moustafa F, Israel: Braester A, Brenner B, Ellis M, Tzoran I, Italy: Barillari G, Bilora F, Bortoluzzi C, Brandolin B, Bucherini E, Camerota A, Ciammaichella M, Dentali F, Di Micco P, Grandone E, Imbalzano E, Lessiani G, Maida R, Mastroiacovo D, Ngoc V, Pace F, Parisi R, Pesavento R, Pinelli M, Prandoni P, Quintavalla R, Rocci A, Siniscalchi C, Sotgiu P, Tufano A, Visonà A, LATVIA: Gibietis V, Skride A, Strautmane S, Republic of Macedonia: Bosevski M, Zdraveska M, Switzerland: Bounameaux H, Mazzolai L, USA: Caprini J, Vietnam: Bui HM.

Funding

This study was funded by Sanofi Spain with an unrestricted educational grant and Bayer Pharma AG. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain, which accounts for a 25.02% of the total patients included in the RIETE Registry.

Compliance with ethical standards

Conflict of interest

Ido Weinberg serves on the Scientific Advisory Board, Novate Medical. Jay Giri serves on the Board of Directors for PERT Consortium, a 501c3 not-for-profit organization. Raghu Kolluri serves on the Board of Directors for VIVA Physicians Inc, a 501c3 not-for-profit organization. He is a paid consultant or serves on the Advisory Board for Medtronic, Philips/Volcano, BTG, Janssen, Vesper Medical, Innovein, Spectranetics, Inari, Boston Scientific. He has received research support from BTG. Juan Ignacio Arcelus, Conxita Falgá, Silvia Soler, Andrei Braester, José Bascuñana, Javier Gutiérrez-Guisado and Manuel Monreal declares no conflicts of interests.

Informed consent

Participating centers have local Institutional Review Board approval with patients providing informed consent for registry enrollment.

References

  1. 1.
    Delis KT, Hunt N, Strachan RK, Nicolaides AN (2001) Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy. Thromb Haemost 86:817–821CrossRefPubMedGoogle Scholar
  2. 2.
    Kim S, Bosque J, Meehan JP, Jamali A, Marder R (2011) Increase in outpatient knee arthroscopy in the United States: a comparison of National Surveys of Ambulatory Surgery, 1996 and 2006. J Bone Joint Surg Am 93:994–1000CrossRefPubMedGoogle Scholar
  3. 3.
    van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, Nelissen R, Cannegieter SC (2017) Pot K and Group P-C. thromboprophylaxis after knee arthroscopy and lower-leg casting. N Engl J Med 376:515–525CrossRefPubMedGoogle Scholar
  4. 4.
    Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J, Jiang Q (2014) Incidence of symptomatic and asymptomatic venous thromboembolism after elective knee arthroscopic surgery: a retrospective study with routinely applied venography. Arthroscopy 30:818–822CrossRefPubMedGoogle Scholar
  5. 5.
    Graham WC, Flanigan DC (2014) Venous thromboembolism following arthroscopic knee surgery: a current concepts review of incidence, prophylaxis, and preoperative risk assessment. Sports Med 44:331–343CrossRefPubMedGoogle Scholar
  6. 6.
    Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J (1998) Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 158:47–50CrossRefPubMedGoogle Scholar
  7. 7.
    Jameson SS, Dowen D, James P, Serrano-Pedraza I, Reed MR, Deehan D (2012) Complications following anterior cruciate ligament reconstruction in the English NHS. Knee 19:14–19CrossRefPubMedGoogle Scholar
  8. 8.
    Ilahi OA, Reddy J, Ahmad I (2005) Deep venous thrombosis after knee arthroscopy: a meta-analysis. Arthroscopy 21:727–730CrossRefPubMedGoogle Scholar
  9. 9.
    Ye S, Dongyang C, Zhihong X, Dongquan S, Jin D, Jianghui Q, Jizhen Q, Pu Y, Huacheng H, Wei S, Qing J (2013) The incidence of deep venous thrombosis after arthroscopically assisted anterior cruciate ligament reconstruction. Arthroscopy 29:742–747CrossRefPubMedGoogle Scholar
  10. 10.
    van Adrichem RA, Nelissen RG, Schipper IB, Rosendaal FR, Cannegieter SC (2015) Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study. J Thromb Haemost 13:1441–1448CrossRefPubMedGoogle Scholar
  11. 11.
    Seon JK, Song EK, Yoon TR, Park SJ, Seo HY (2006) An unusual case of pulmonary embolism after arthroscopic meniscectomy. Arch Orthop Trauma Surg 126:641–643CrossRefPubMedGoogle Scholar
  12. 12.
    Takigami J, Hashimoto Y, Yamasaki S, Terai S, Nakamura H (2017) A case of asymptomatic bilateral massive pulmonary embolism after arthroscopic multiple knee ligament reconstruction. Knee Surg Sports Traumatol Arthrosc 25:260–262CrossRefPubMedGoogle Scholar
  13. 13.
    Poulsen KA, Borris LC, Lassen MR (1993) Thromboembolic complications after arthroscopy of the knee. Arthroscopy 9:570–573CrossRefPubMedGoogle Scholar
  14. 14.
    Egermayer P (1999) Mortality of untreated deep vein thrombosis following knee arthroscopy. Chest 115:604CrossRefPubMedGoogle Scholar
  15. 15.
    Navarro-Sanz A, Fernandez-Ortega JF (2004) Fatal pulmonary embolism after knee arthroscopy. Am J Sports Med 32:525–528CrossRefPubMedGoogle Scholar
  16. 16.
    Rozencwaig R, Shilt JS, Ochsner JL Jr (1996) Fatal pulmonary embolus after knee arthroscopy. Arthroscopy 12:240–241CrossRefPubMedGoogle Scholar
  17. 17.
    Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J, Qin J, Jiang Q (2014) Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. Arthroscopy 30:406–412CrossRefPubMedGoogle Scholar
  18. 18.
    Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM, Group KS (2008) Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 149:73–82CrossRefPubMedGoogle Scholar
  19. 19.
    Camporese G, Bernardi E, Noventa F, Bosco M, Monteleone G, Santoro L, Bortoluzzi C, Freguja S, Nardin M, Marullo M, Zanon G, Mazzola C, Damiani G, Maniscalco P, Imberti D, Lodigiani C, Becattini C, Tonello C, Agnelli G, Group ES (2016) Efficacy of rivaroxaban for thromboprophylaxis after knee arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study. Thromb Haemost 116:349–355CrossRefPubMedGoogle Scholar
  20. 20.
    Cancienne JM, Diduch DR, Werner BC (2017) High altitude is an independent risk factor for postoperative symptomatic venous thromboembolism after knee arthroscopy: a matched case–control study of medicare patients. Arthroscopy 33:422–427CrossRefPubMedGoogle Scholar
  21. 21.
    Krych AJ, Sousa PL, Morgan JA, Levy BA, Stuart MJ, Dahm DL (2015) Incidence and risk factor analysis of symptomatic venous thromboembolism after knee arthroscopy. Arthroscopy 31:2112–2118CrossRefPubMedGoogle Scholar
  22. 22.
    Mauck KF, Froehling DA, Daniels PR, Dahm DL, Ashrani AA, Crusan DJ, Petterson TM, Bailey KR, Heit JA (2013) Incidence of venous thromboembolism after elective knee arthroscopic surgery: a historical cohort study. J Thromb Haemost 11:1279–1286CrossRefPubMedGoogle Scholar
  23. 23.
    Gaskill T, Pullen M, Bryant B, Sicignano N, Evans AM, DeMaio M (2015) The prevalence of symptomatic deep venous thrombosis and pulmonary embolism after anterior cruciate ligament reconstruction. Am J Sports Med 43:2714–2719CrossRefPubMedGoogle Scholar
  24. 24.
    Bikdeli B, Jimenez D, Hawkins M, Ortiz S, Prandoni P, Brenner B, Decousus H, Masoudi FA, Trujillo-Santos J, Krumholz HM, Monreal M, Investigators R, Rationale (2018) Design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 118:214–224CrossRefPubMedGoogle Scholar
  25. 25.
    Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694CrossRefPubMedGoogle Scholar
  26. 26.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352CrossRefPubMedGoogle Scholar
  27. 27.
    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton III LJ (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160:761–768CrossRefPubMedGoogle Scholar
  28. 28.
    Nemeth B, van Adrichem RA, Cannegieter SC (2016) The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy. Thromb Haemost 116:1001CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ido Weinberg
    • 1
  • Jay Giri
    • 2
  • Raghu Kolluri
    • 3
  • Juan Ignacio Arcelus
    • 4
  • Conxita Falgá
    • 5
  • Silvia Soler
    • 6
  • Andrei Braester
    • 7
  • José Bascuñana
    • 8
  • Javier Gutiérrez-Guisado
    • 9
    • 10
  • Manuel Monreal
    • 11
    • 12
  • RIETE Investigators
  1. 1.Vascular Medicine, Division of Cardiology, Fireman Vascular CenterMassachusetts General HospitalBostonUSA
  2. 2.Division of Cardiology, Penn Cardiovascular Outcomes, Quality, & Evaluative Research Center, Leonard Davis Institute of Health EconomicsUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.OhioHealth Vascular InstituteOhio HealthColumbusUSA
  4. 4.Department of General SurgeryHospital Universitario Virgen de las NievesGranadaSpain
  5. 5.Department of Internal MedicineHospital de MataróBarcelonaSpain
  6. 6.Department of Internal MedicineHospital Olot i Comarcal de la GarrotxaGironaSpain
  7. 7.Department of HaematologyGalilee Medical CenterNahariyaIsrael
  8. 8.Department of Internal MedicineHospital Universitario Infanta LeonorMadridSpain
  9. 9.Department of Internal MedicineHospital Monográfico ASEPEYOMadridSpain
  10. 10.Universidad Francisco de VitoriaMadridSpain
  11. 11.Department of Internal MedicineHospital Germans Trias i PujolBarcelonaSpain
  12. 12.Universidad Católica de MurciaMurciaSpain

Personalised recommendations